Plasma selenium Archives - Seleniumfacts.com

In cancer prevention, there seems to be a U-shaped response to selenium supplementation. The threat of adversity is greater at the lower and higher levels of serum/plasma selenium. For example, Emily Chiang and her colleagues posit that the optimal serum selenium level for the reduction of prostate cancer risk is between 119 and 137 micrograms per liter. (Graph for illustration purposes only)

The documentation in various systematic reviews and meta-analyses of selenium and cancer studies shows a significant inverse association between selenium intake and/or plasma/serum selenium status and cancer [Lee; Hurst; Cai].

There is some evidence of a U-shaped relationship between plasma/serum selenium status and protection against cancer [Hurst; Rayman]. Low plasma/serum selenium status clearly correlates with higher risk of cancer. High plasma/serum selenium status correlates with no increased protective effect against cancer. The key is to find the supplement doses and subsequent plasma/serum status that give the best protection in between the two extremes.

Evaluating the evidence from published studies is complicated. We need to remember that the following factors affect the relationship between selenium status and/or intake and cancer risk: read more

Milestones in early selenium research

1817 Swedish chemist Jöns Jakob Berzelius discovers selenium

1957 Biochemist Klaus Schwarz shows that selenium in microscopic amounts has a vital importance for mammalian health

1969 Professor J.T. Rotruck discovers that selenium has a biochemical role as a component of the antioxidant enzyme glutathione peroxidase

1969 Professors R.J. Shamberger and D.V. Frost report a possible protective effect of selenium against cancer in humans

1973 Professor J.T. Rotruck identifies the enzyme glutathione peroxidase as a selenium-dependent protein

1977 Professor G.N. Schrauzer publishes cancer mortality correlation studies showing an inverse correlation between dietary intakes of selenium and cancer mortality in 27 countries

1988 Professor G.Q Yang summarizes the lessons learned about the selenium-related endemic diseases Keshan disease and Kashin-Beck disease and about the importance of adequate daily selenium intakes

1989 Professor G.G. Duthie publishes evidence for a role of selenium in the prevention of cardiovascular disease

1993 Researcher W.J. Blot publishes the results of the Nutrition Intervention Trials in Linxian, China, showing that supplementation with a combination of selenium and other antioxidants reduces the risk of cancer

1994 Professor G.N. Schrauzer publishes evidence that selenium is important in the maintenance and therapy of HIV-infected patients

1996 Professor Larry Clark publishes the results of a randomized controlled trial – the Nutritional Prevention of Cancer study -- that shows selenium's cancer-protective effects on colon cancer, lung cancer, and prostate cancer

1997 Professor G.F. Combs summarizes the evidence for the protective effects of selenium against cancer

1999 Professor J.E. Oldfield publishes his Selenium World Atlas, mapping areas of selenium deficiency around the world

2000 Researcher O.A. Levander publishes evidence showing an anti-viral effect of selenium

2002 Researcher R. Gärtner shows that supplementation with selenium reduces inflammation in patients with autoimmune thyroiditis

2002 Researcher Margaret Rayman presents the arguments for increasing selenium intakes to realize selenium’s antioxidant and anti-viral and anti-inflammatory effects as well as selenium’s enhancement of immune function and reproductive success.

Tag: Plasma selenium

Serum/plasma selenium status and protection against cancer